Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 |
|---|---|
| Revenue | $36K 100.0% |
| Cost of Revenue | $29.7M 82693.7% |
| Gross Profit | $5.7M 15845.8% |
| Selling, General & Admin | $1.4M 3775.9% |
| Total Operating Expenses | $1.4M 3775.9% |
| Operating Income | $4.3M 12069.8% |
| Pretax Income | $4.3M 12033.1% |
| Income Tax Expense | $649K 1807.1% |
| Net Income | $3.7M 10226.0% |
| Per Share | |
| EPS (Basic) | $0.18 |
| EPS (Diluted) | $0.18 |
| Weighted Avg Shares (Basic) | 20.4M |
| Weighted Avg Shares (Diluted) | 20.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-10-30
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 37% against ROIC 33% — 5% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Each line as % of revenue — the trend in color
| % of revenue | FY2025 |
|---|---|
| Cost of Revenue | 82693.7 |
| Gross Profit | 15845.8 |
| SG&A | 3775.9 |
| Operating Income | 12069.8 |
| Income Tax | 1807.1 |
| Net Income | 10226.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on JLHL: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow on any basis, so a reverse DCF can't be run.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash of $8.7M fully covers short-term debt of $1.4M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Ranked against 37 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IQV | $44.1B | 34.1× | 17.4× | 2.7× | 5.9% | — | 8.3% | 20.9% | 6.1% | 4.1× | 319 |
| PAYX | $39.9B | 22.9× | 14.7× | 6.1× | 16.9% | 74.3% | 27.0% | 47.1% | 21.2% | 1.2× | 517 |
| INCY | $24.4B | 18.8× | 13.3× | 4.8× | 21.2% | 92.8% | 25.0% | 24.9% | 24.9% | -1.9× | 239 |
| MEDP | $18.2B | 42.7× | 31.6× | 7.2× | 20.0% | — | 17.8% | 98.3% | 98.3% | -0.9× | 174 |
| CRL | $17.2B | — | 39.5× | 4.3× | -0.9% | — | -3.6% | -4.6% | -4.6% | -0.5× | 132 |
| ICLR | $15.8B | 72.9× | 21.9× | 1.9× | 0.8% | — | 2.8% | 2.5% | 1.9% | 2.7× | 86 |
| ULS | $15.1B | 46.7× | 21.5× | 4.9× | 6.4% | 49.5% | 10.6% | 25.8% | 18.5% | 0.3× | 72 |
| IT | $14.4B | 23.7× | 12.8× | 2.2× | 3.7% | 68.8% | 11.2% | 228% | 22.1% | 1.0× | 163 |
| BAH | $10.5B | 12.8× | 11.5× | 0.9× | -6.4% | 52.7% | 7.6% | 77.0% | 16.9% | 2.7× | 118 |
| TTEK | $9.9B | 41.6× | 22.5× | 1.8× | 4.7% | 17.7% | 4.6% | 13.9% | 9.7% | 1.3× | 123 |
| ACM | $8.2B | 15.1× | 6.2× | 0.5× | 0.2% | 7.5% | 3.5% | 22.5% | 22.5% | -1.5× | 125 |
| G | $6.6B | 12.7× | 8.9× | 1.3× | 6.6% | 36.0% | 10.9% | 21.7% | 13.5% | 0.8× | 112 |
| FCN | $5.0B | 22.2× | 11.7× | 1.3× | 2.4% | 32.1% | 7.1% | 15.6% | 12.9% | 0.2× | 66 |
| VSEC | $4.1B | 268.8× | 33.8× | 3.7× | 41.5% | — | 1.1% | 0.8% | 0.7% | 1.7× | 74 |
| EXPO | $3.8B | 38.8× | — | 6.6× | 4.2% | — | 18.2% | 27.2% | 27.2% | — | 76 |
| HURN | $3.1B | 33.3× | 17.0× | 1.8× | 11.7% | — | 6.2% | 19.9% | 10.1% | 2.3× | 48 |
| VVX | $2.5B | 32.8× | 17.1× | 0.6× | 3.7% | 8.3% | 1.7% | 7.2% | 3.6% | 5.2× | 62 |
| NEO | $2.2B | — | — | 3.1× | 10.1% | 43.2% | -14.9% | -12.9% | -9.2% | — | 56 |
| ASTH | $1.8B | 79.4× | 19.5× | 0.6× | 56.4% | — | 0.7% | 2.9% | 1.2% | 4.9× | 35 |
| ICFI | $1.7B | 19.3× | 10.4× | 0.9× | -7.3% | 37.2% | 4.9% | 8.9% | 6.4% | 1.9× | 35 |
| WLDN | $1.1B | 21.1× | 17.6× | 1.6× | 20.5% | 37.5% | 7.7% | 17.2% | 14.9% | -0.3× | 37 |
| BWMN | $712M | 58.8× | 20.6× | 1.4× | 14.9% | 53.4% | 2.6% | 4.9% | 4.0% | 1.3× | 22 |
| MG | $643M | 38.1× | 11.1× | 0.9× | -0.8% | 28.2% | 2.3% | 7.2% | 4.1% | 2.1× | 24 |
| ONT | $524M | — | 33.3× | 0.6× | 19.3% | 40.3% | -0.1% | -0.2% | -0.1% | 11.5× | — |
| NRC | $506M | 0.5× | — | 3.7× | -4.0% | — | 8.4% | 82.9% | 12.5% | — | 22 |
| JLHL | $127M | 31.7× | 27.5× | 3.6× | — | 16.1% | 10.4% | 37.5% | 32.8% | -1.7× | — |
Peers = companies sharing JLHL's sector (Services-Engineering Services) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Earns 103.57pts above its cost of capital, without much margin of safety.
Leverage and buybacks account for 5 points of the 37% return on equity in FY2025. The business earns 33% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
Beta was borrowed from the sector median — too little price history to measure this company's own, so WACC is an estimate of an estimate.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2025-09-30. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: interest_expense.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.